Onkolojik Tedaviye Bağlı Periferik Vasküler Hastalıklar ve İnme

Kostakou PM, Kouris NT, Kostopoulos VS, Damaskos DS, Olympios CD.Cardio-oncology: a newanddevelopingsector of researchandtherapy in thefield of cardiology. Heart 2019 Jan;24(1):91-100

Alexandre J, Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE et al. Cardiovasculartoxicityrelatedtocancer treatment: a pragmaticapproachtotheAmericanandEuropeancardio‐oncology guidelines. J AM HeartAssoc. 2020 Sep 15;9 (18):e018403

Zamorano JL,Lancellotti P, RodriguezMuñoz D, AboyansV et al. TheTask Force forcancertreatmentsandcardiovasculartoxicity of theEuropeanSociety of Cardiology (ESC). EurHeart J.2016 Sep 21;37 (36):2768-2801.

Valent P,Hadzijusufovic E, Hoermann G, FürederW etal.Risk factorsandmechanismscontributingto TKI-inducedvascularevents in patientswith CML. LeukRes. 2017 Aug;59:47-54

O’Hare T, Eide CA, Deininger MW. Bcr-ablkinase domain mutations, drugresistance, andtheroadtoacureforchronicmyeloidleukemia. Blood. 2007;110:2242–9.

Radich JP. Monitoringresponsetotyrosinekinase inhibitör therapy, mutationalanalysis, andnewtreatmentoptions in chronicmyelogenousleukemia. J NatlComprCancNetw. 2013;11:663–6.

Aichberger KJet al. Progressiveperipheralarterialocclusivediseaseandothervasculareventsduringnilotinibtherapy in CML. Am J Hematol. 2011;86:533–9

Kim TD, et al. Peripheralarteryocclusivedisease in chronicphasechronicmyeloidleukemiapatientstreatedwithnilotiniborimatinib. Leukemia. 2013;27:1316–21.

Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, et al. Severe peripheralarterialdiseaseduringnilotinibtherapy. J NatlCancerInst. 2011;103:1347-8.

Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et al. Rates of peripheralarterialocclusivedisease in patientswithchronicmyeloidleukemia in thechronicphasetreatedwithimatinib, nilotinib, ornon-tyrosinekinasetherapy: A retrospectivecohortanalysis. Leukemia. 2013;27:1310–5.

Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascularsafetyissues in CML patientstreatedwith BCR/ABL1 kinaseinhibitors. Blood. 2015;125:901–6.

Mirault T, Rea D, Azarine A, Messas E. Rapidonset of peripheralarterydisease in a chronicmyeloidleukemiapatientwithoutpriorarterialdisorder: Direct relationshipwithnilotinibexposureandclinicaloutcome. Eur J Haematol. 2015;94:363–7.

Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associatedvascularevents. ClinLymphomaMyelomaLeuk. 2012;12:337–40.

Gover-Proaktor A, Granot G, Shapira S, Raz O, Pasvolsky O, Nagler A, et al. Ponatinibreducesviability, migration, andfunctionality of humanendothelialcells. LeukLymphoma. 2017;58:1455–67.

Sekijima T, Tanabe A, Maruoka R, Fujishiro N, Yu S, Fujiwara S, et al. Impact of platinum-basedchemotherapy on theprogression of atherosclerosis. Climacteric. 2011;14:31–40.

Serrano-Castro PJ, Guardado-Santervás P, Olivares-Romero J. Ischemicstrokefollowingcisplatinand 5-fluorouracil therapy: A transcranialdopplerstudy. EurNeurol. 2000;44:63–4.

El Amrani M, Heinzlef O, Debroucker T, Roullet E, Bousser MG, Amarenco P. Brain infarctionfollowing 5-fluorouracil andcisplatintherapy. Neurology. 1998;51:899–901.

Kinno R, Kii Y, Uchiyama M, Owan Y, Yamazaki T, Fukui T. 5-fluorouracil-induced leukoencephalopathywithacutestroke-likepresentationfulfillingcriteriaforrecombinanttissueplasminogenactivatortherapy. J StrokeCerebrovascDis. 2014;23:387–9.

Li J, Lee JJ, Chu E, Baehring JM. Reversibleleukoencephalopathywithstroke-likepresentation in a patientwith 5-dihydropyrimidine dehydrogenasedeficiencytreatedwithcontinuous 5-fluorouracil infusion. ClinColorectalCancer. 2012;11:215–7.

Nguyen MT, Stoianovici R, Brunetti L. Chemotherapyinducedstrokemimic: 5-fluorouracil encephalopathyfulfillingcriteriafortissueplasminogenactivatortherapy. Am J EmergMed. 2017;35:1389–90.

Fraum TJ, KreislTN, Sul J, Fine HA, Iwamoto FM. Ischemicstrokeandintracranialhemorrhage in gliomapatients on antiangiogenictherapy. J Neurooncol. 2011;105:281–9.

Letarte N, Bressler LR, Villano JL. Bevacizumabandcentralnervoussystem (CNS) hemorrhage. CancerChemotherPharmacol. 2013;71:1561–5.

Kuenen BC. Analysis of prothromboticmechanismsandendothelialperturbationduringtreatmentwithangiogenesisinhibitors. PathophysiolHaemostThromb. 2003;33(Suppl 1):13–4.

DiLisi D, Madonna R, Zito C, Bronte E, Badalamenti G, Parrella P, et al. Anticancertherapy-inducedvasculartoxicity: VEGF inhibitionandbeyond. Int J Cardiol. 2017;227:11–7

Chaosuwannakit N, D’Agostino R, Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, et al. Aorticstiffnessincreasesuponreceipt of anthracyclinechemotherapy. J ClinOncol. 2010;28:166–72.

Drafts BC, Twomley KM, D’Agostino R, Jr, Lawrence J, Avis N, Ellis LR, et al. Lowtomoderatedoseanthracycline-basedchemotherapy is associatedwithearlynoninvasiveimagingevidence of subclinicalcardiovasculardisease. JACC CardiovascImaging. 2013;6:877–85.

Grover S, Lou PW, Bradbrook C, Cheong K, Kotasek D, Leong DP, et al. Earlyandlatechanges in markers of aorticstiffnesswithbreastcancertherapy. InternMed J. 2015;45:140–7

Gao Y, Ma G, Liu S, Teng Y, Wang Y, Su Y. Thalidomideandmultiplemyeloma serum synergisticallyinduce a hemostaticimbalance in endothelialcells in vitro.ThrombRes. 2015;135:1154–9.

De Bruin ML, Dorresteijn LD, van’tVeer MB, Krol AD, van der Pal HJ, Kappelle AC, et al. Increased risk of strokeandtransientischemicattack in 5-year survivors of hodgkinlymphoma. J NatlCancerInst. 2009;101:928–37.

Woodward WA, Durand JB, Tucker SL, Strom EA, Perkins GH, Oh J, et al. Prospectiveanalysis of carotidarteryflow in breastcancerpatientstreatedwithsupraclavicularirradiation 8 ormoreyearspreviously: No increase in ipsilateralcarotidstenosisafterradiationnoted. Cancer. 2008;112:268–73.

Levinson SA, Close MB, Ehrenfeld WK, Stoney RJ. Carotidarteryocclusivediseasefollowingexternalcervicalirradiation. ArchSurg. 1973;107:395–7.

Hayward RH. Arteriosclerosisinducedbyradiation. SurgClin North Am. 1972;52:359–66.

Cheng SW, Ting AC, Wu LL. Ultrasonicanalysis of plaquecharacteristicsandintimal-medialthickness in radiation-inducedatheroscleroticcarotidarteries. Eur J VascEndovascSurg. 2002;24:499–504.

Fonkalsrud EW, Sanchez M, Zerubavel R, Mahoney A. Serialchanges in arterialstructurefollowingradiationtherapy. SurgGynecolObstet. 1977;145:395–400.

Louis EL, McLoughlin MJ, Wortzman G. Chronicdamagetomediumandlargearteriesfollowingirradiation. J Can AssocRadiol. 1974;25:94–104.

Fajardo LF. Thepathology of ionizingradiation as definedbymorphologicpatterns. ActaOncol. 2005;44:13–22.